cancer cell detection News
-
NIH/NCI Small Business Innovation Research Grant, Awarded Fall 2019
Nodexus was selected for an SBIR grant for the development of a novel cancer stem cell detection and isolation platform leveraging the core Nodexus technology ...
By Nodexus Inc.
-
Frédéric Leblond in the running for discovery of the year
The cancer cell detection probe developed by Louperivois Frédéric Leblond and Kevin Petrecca, of Polytechnique Montreal and the Montreal Neurological Institute and Hospital, could well be the discovery of the year in Quebec. Quebec Science magazine invites the public to vote for the discovery of the year 2017. The jury of experts brought together by the magazine selected 10 ...
-
Detecting the previously undetectable
Combining engineering and medicine can lead to world-leading tools like the Raman spectroscopy, which can help to distinguish cancer cells from healthy cells; for example, in brain tumour surgery.ISTOCKPHOTO / GETTY IMAGES One of the biggest challenges in brain tumour surgery is making sure that all cancer cells are removed. “If you leave a few cancer cells behind, the cancer will come ...
-
Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon Biosystems, a pioneer of liquid biopsy ...
-
Dako, an Agilent Technologies Company, Announces FDA Approval of New Companion Diagnostic for Lung Cancer
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration (FDA) approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer (NSCLC) is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of ...
-
Results and Presentation of Important New Research at the 2018 IASLC World Conference on Lung Cancer
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC), 23-26 September in Toronto, Canada. These studies demonstrate important new morphometric detection findings of the Cell-CT™ platform and the LuCED® ...
-
Cellular Imaging Platform Detects the Presence of Cancer-Associated Cells that have undergone Malignancy Associated Change
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, today presented a breakthrough research study demonstrated its CellCT™ platform can detect subtle changes in cellular and nuclear morphology of cancer-associated cells (CACs) as a result of the cancer field effect. These non-cancerous cells have been affected by the presence of the cancer cells and have undergone ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you